Latest Articles
The association between endometrial polyps and insulin resistance from the expression of PI3K and AKT proteins perspective - BioMed Central
The association between endometrial polyps and insulin resistance from the expression of PI3K and AKT proteins perspective BioMed Central
Published: June 22, 2024, 7 a.m.
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer - OncLive
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay
Published: June 21, 2024, 7 a.m.
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer - OncLive
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma - OncLive
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma OncLive
Published: June 20, 2024, 7 a.m.
ASCO 2024: New Insights Into Endometrial Cancer Treatment and Etiology - Cancer Therapy Advisor
ASCO 2024: New Insights Into Endometrial Cancer Treatment and Etiology Cancer Therapy Advisor
Published: June 20, 2024, 7 a.m.
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients - BioPharm International
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients BioPharm International
Published: June 20, 2024, 7 a.m.
Novotech Publishes Report on Research into Endometrial - GlobeNewswire
Novotech Publishes Report on Research into Endometrial GlobeNewswire
Published: June 20, 2024, 7 a.m.
FDA Approves Two First-Line Immunotherapies for Endometrial Cancer - Cancer Health Treatment News
FDA Approves Two First-Line Immunotherapies for Endometrial Cancer Cancer Health Treatment News
Published: June 20, 2024, 7 a.m.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers
Published: June 20, 2024, 7 a.m.
Link copied to clipboard!